Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
OpenAI launches drug development AI model
OpenAI is launching an early version of an artificial intelligence (AI) model aimed at accelerating drug discovery. The model is called GPT-Rosalind, targeting life sciences research, such as helping extract insights from massive data and transforming scientific research into patient-oriented medical applications. OpenAI states that the model will first be available to some enterprise customers in a research preview. The initial users include pharmaceutical company Amgen, vaccine manufacturer Moderna, and the nonprofit biological research organization Allen Institute. OpenAI, Anthropic, and Google under Alphabet are increasingly focusing on the application of AI in science and medicine, including assisting in new drug development and analyzing personal medical data. (Sina Finance)